Evidence map›Paper›PMID 36372246›Full record

ArticleAmerican heart journal2023

Predicting short-term outcomes after transcatheter aortic valve replacement for aortic stenosis.

Samuel T Savitz, Thomas Leong, Sue Hee Sung, Dalane W Kitzman, Edward McNulty, Jacob Mishell, Andrew Rassi, Andrew P Ambrosy, Alan S Go

Open access · greenAbstract read
In one paragraph

Article in American heart journal, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.5field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 4 citations in OpenAlex.

  1. Immune Aging is an Independent Risk Factor for Cardiovascular Disease.bioRxiv : the preprint server for biology · 2026
    Article
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 4 institutions in 1 country.

Samuel T SavitzDivision of Research, Kaiser Permanente Northern California, Oakland, CA; Robert D. and Patricia E. Kern Center for the Science of Health Care Delivery, Mayo Clinic, Rochester, MN; Division of Health Care Delivery Research, Mayo Clinic, Rochester, MN.
Thomas LeongDivision of Research, Kaiser Permanente Northern California, Oakland, CA.
Sue Hee SungDivision of Research, Kaiser Permanente Northern California, Oakland, CA.
Dalane W KitzmanSection on Cardiovascular Medicine, Wake Forest School of Medicine, Winston-Salem, NC.
Edward McNultyKaiser Permanente San Francisco Medical Center, San Francisco, CA.
Jacob MishellKaiser Permanente San Francisco Medical Center, San Francisco, CA.
Andrew RassiKaiser Permanente San Francisco Medical Center, San Francisco, CA.
Andrew P AmbrosyDivision of Research, Kaiser Permanente Northern California, Oakland, CA; Kaiser Permanente San Francisco Medical Center, San Francisco, CA.
Alan S GoDivision of Research, Kaiser Permanente Northern California, Oakland, CA; Department of Medicine, University of California, San Francisco, CA; Department of Health Systems Science, Kaiser Permanente Bernard J. Tyson School of Medicine, Pasadena, CA; Departments of Epidemiology, Biostatistics and Medicine, University of California, San Francisco, CA; Department of Medicine, Stanford University, Palo Alto, CA. Electronic address: alan.s.go@kp.org.
Kaiser Permanente San Francisco Medical Center · USKaiser Permanente · USMayo Clinic in Arizona · USWake Forest University · US

Funding

Wake Forest Claude D. Pepper OAIC - RenewalP30AG021332 · NIA · WAKE FOREST UNIVERSITY HEALTH SCIENCES · PI Denise Kathryn Houston · 2002 to 2026
$36.4M
Preparing For What Is Next With Aducanumab In Real World SettingsR33AG057806 · NIA · UNIV OF MASSACHUSETTS MED SCH WORCESTER · PI Christopher Barrett Bowling, Ana Roman Quinones · 2018 to 2026
$9.0M
REHAB-HF: A Trial of Rehabilitation Therapy in Older Acute Heart Failure PatientsR01AG045551 · NIA · WAKE FOREST UNIVERSITY HEALTH SCIENCES · PI KITZMAN, DALANE W · 2014 to 2018
$6.8M
Pepper OAIC Coordinating CenterU24AG059624 · NIA · WAKE FOREST UNIVERSITY HEALTH SCIENCES · PI DALANE W KITZMAN · 2018 to 2026
$6.0M
Exercise Intolerance in Older HFPEF PatientsR01AG018915 · NIA · WAKE FOREST UNIVERSITY HEALTH SCIENCES · PI KITZMAN, DALANE W · 2001 to 2019
$5.2M
Outpatient Worsening Heart Failure in an Integrated Health Care Delivery System: An Innovative Approach to Characterizing a Novel Clinical EntityK23HL150159 · NHLBI · KAISER FOUNDATION RESEARCH INSTITUTE · PI AMBROSY, ANDREW PATRICK · 2020 to 2024
$962k
NHLBI NIH HHS K23 HL150159NIA NIH HHS P30 AG021332NIA NIH HHS R01 AG018915NIA NIH HHS R01 AG045551NIA NIH HHS R33 AG057806NIA NIH HHS U24 AG059624
6 · The paper itself

Abstract

backgroundThe approved use of transcatheter aortic valve replacement (TAVR) for aortic stenosis has expanded substantially over time. However, gaps remain with respect to accurately delineating risk for poor clinical and patient-centered outcomes. Our objective was to develop prediction models for 30-day clinical and patient-centered outcomes after TAVR within a large, diverse community-based population.

methodsWe identified all adults who underwent TAVR between 2013-2019 at Kaiser Permanente Northern California, an integrated healthcare delivery system, and were monitored for the following 30-day outcomes: all-cause death, improvement in quality of life, all-cause hospitalizations, all-cause emergency department (ED) visits, heart failure (HF)-related hospitalizations, and HF-related ED visits. We developed prediction models using gradient boosting machines using linked demographic, clinical and other data from the Society for Thoracic Surgeons (STS)/American College of Cardiology (ACC) TVT Registry and electronic health records. We evaluated model performance using area under the curve (AUC) for model discrimination and associated calibration plots. We also evaluated the association of individual predictors with outcomes using logistic regression for quality of life and Cox proportional hazards regression for all other outcomes.

resultsWe identified 1,565 eligible patients who received TAVR. The risks of adverse 30-day post-TAVR outcomes ranged from 1.3% (HF hospitalizations) to 15.3% (all-cause ED visits). In models with the highest discrimination, discrimination was only moderate for death (AUC 0.60) and quality of life (AUC 0.62), but better for HF-related ED visits (AUC 0.76). Calibration also varied for different outcomes. Importantly, STS risk score only independently predicted death and all-cause hospitalization but no other outcomes. Older age also only independently predicted HF-related ED visits, and race/ethnicity was not significantly associated with any outcomes.

conclusionsDespite using a combination of detailed STS/ACC TVT Registry and electronic health record data, predicting short-term clinical and patient-centered outcomes after TAVR remains challenging. More work is needed to identify more accurate predictors for post-TAVR outcomes to support personalized clinical decision making and monitoring strategies.

Indexed as

Aortic Valve StenosisHeart FailureTranscatheter Aortic Valve ReplacementAortic ValveHumansQuality of LifeRegistriesRisk FactorsTreatment OutcomeUnited States

Identifiers

PMID36372246
PMCPMC9840674
OpenAlexW4308785755

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.